

Supplementary Table 1. Clinical characteristics of 36 patients with gastric cancer.

Variable	No. of patients
Gender (male/female)	21/15
Age (years; median, range)	57, 32-74
CEA (U/L; <5/≥5)	22/14
Tumor size (cm; <5/≥5)	23/13
<i>H.pylori</i> antibody (positive vs. negative)	10/26
Histological type (differentiated/undifferentiated)	17/19
Lymphatic invasion (absent/present)	18/18
Vascular invasion (absent/present)	13/23
Tumor (T) invasion (T1+T2/T3+T4)	15/21
Lymphoid Nodal (N) status (N0+N1/N2+N3)	19/17
Distant metastasis (M) status (M0/M1)	33/3
TNM stage (I + II / III + IV)	16/20
IL-6 production <sup>a</sup> (median, range)	38.49, 16.4-105.7
IL-6 <sup>+</sup> cell <sup>b</sup> (median, range)	163.5, 64-243
CD163 <sup>+</sup> macrophage <sup>c</sup> (median, range)	34, 8-67
CD163 <sup>+</sup> CD206 <sup>+</sup> macrophage <sup>d</sup> (median, range)	17, 2-28

<sup>a</sup>IL-6 production was the concentration of IL-6 (pg/mg) of tumor tissues by ELISA. <sup>b</sup>IL-6<sup>+</sup> cell was the number of IL-6<sup>+</sup> cell per field of tumor tissues by immunochemistry. <sup>c</sup>CD163<sup>+</sup> macrophage was the number of CD163<sup>+</sup> macrophage per field of tumor tissues by immunochemistry. <sup>d</sup>CD163<sup>+</sup>CD206<sup>+</sup> macrophage was the number of CD163<sup>+</sup>CD206<sup>+</sup> macrophage per field of tumor tissues by immunochemistry. CEA, carcinoembryonic antigen.